GUFICBIO
Gufic Biosciences Limited
Each stock's 10,000-path forecast, rendered as light.
Gufic Biosciences Limited (GUFICBIO) Stock Analysis & Case Study
Is GUFICBIO a good buy? The data-driven verdict.
Gufic Biosciences Limited (GUFICBIO) trades at ₹421,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Gufic Biosciences Limited (GUFICBIO) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 65.8× earnings, ROE of 10.1%, a 56% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
GUFICBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How GUFICBIO ranks against the 2,373 companies in our screener
- GUFICBIO's market cap of 4,226 Cr ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's book value of ₹66 ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's promoter holding of 72.5% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's 3-year profit (PAT) growth of 15.0% ranks in the 49th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's 3-year revenue growth of 15.0% ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's debt-to-equity ratio of 0.61x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is GUFICBIO overvalued? GUFICBIO P/E vs peers
GUFICBIO trades at 65.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
GUFICBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of GUFICBIO history (24%/yr drift, 38%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GUFICBIO 2027 | ₹276 | ₹444 | ₹717 | +5% |
| GUFICBIO 2028 | ₹234 | ₹469 | ₹937 | +11% |
| GUFICBIO 2029 | ₹212 | ₹494 | ₹1,152 | +17% |
| GUFICBIO 2030 | ₹195 | ₹521 | ₹1,393 | +24% |
| GUFICBIO 2031 | ₹186 | ₹550 | ₹1,630 | +30% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GUFICBIO goes up, or doubles?
The bull case for GUFICBIO
- Gufic Biosciences Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,152.
The bear case & risks
- GUFICBIO's P/E of 65.8x is lower than 19% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GUFICBIO's return on equity of 10.1% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹212.
GUFICBIO volatility & expected range, how bumpy is the ride?
Over the last 9.8 years GUFICBIO compounded at 24%/year with annualized volatility of 38%. That volatility implies a 1-year 80% range of ₹276-₹717, the honest backbone behind any single price target.
GUFICBIO price forecast, the full 60-month probability fan
GUFICBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GUFICBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the GUFICBIO price target & forecast page.
GUFICBIO Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. GUFICBIO scores 6/8, mixed financial health.
GUFICBIO MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy GUFICBIO with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 50.00% | 2.0× |
| Groww | 32.78% | 3.1× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 100.00% | 1.0× |
| Pocketful | 50.00% | 2.0× |
| Fyers | 50.00% | 2.0× |
| Anand Rathi | 32.77% | 3.1× |
| Bajaj Broking | 42.00% | 2.4× |
| Share IndiaCHEAPEST | 32.73% | 3.1× |
Compare every broker on the GUFICBIO MTF page.
About Gufic Biosciences Limited: sector, index & market-cap context
Gufic Biosciences Limited (GUFICBIO) is a small-cap NSE-listed company, with a market capitalisation of ₹4,226 Cr. See more stocks on our screener.
How the GUFICBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Gufic Biosciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GUFICBIO analysis, FAQs
Is Gufic Biosciences Limited (GUFICBIO) a good buy?
On the numbers, Gufic Biosciences Limited (GUFICBIO) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 65.8× earnings, ROE of 10.1%, a 56% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GUFICBIO overvalued or undervalued?
GUFICBIO trades at 65.8× earnings, expensive versus the ~22× long-run Nifty average.
What is the GUFICBIO share price target for 2031?
GUFICBIO's probability-weighted 2031 median target is ₹550, with an 80% range of ₹186-₹1,630 (10,000-path Monte-Carlo).
What is the probability GUFICBIO doubles in 5 years?
The modelled probability of GUFICBIO reaching ₹843 (2×) within 5 years is 31%.
What is the bull case for GUFICBIO?
Gufic Biosciences Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in GUFICBIO?
GUFICBIO's P/E of 65.8x is lower than 19% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. GUFICBIO's return on equity of 10.1% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.